Actively Recruiting
Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC
Led by The First Affiliated Hospital of Xiamen University · Updated on 2025-07-01
208
Participants Needed
3
Research Sites
252 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This prospective, phase II, multicenter, randomized controlled study aims to compare the complete response rate and long-term survival outcomes of two-cycle and three-cycle induction therapy with modified TPF regimens combined with camrelizumab in patients with locally advanced nasopharyngeal carcinoma.
CONDITIONS
Official Title
Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 65 years old
- Pathologically confirmed nasopharyngeal carcinoma with clinical stage T1-4N2-3M0
- No previous systemic treatment such as surgery, radiotherapy, or chemotherapy
- At least one measurable lesion on imaging according to RECIST criteria version 1.1
- ECOG Performance Status of 0 or 1
- Expected survival of at least 3 months
- Use of contraception from first dose until 24 weeks after last dose for males and women of childbearing potential
- Normal major organ function with acceptable results in hematology, biochemistry, and coagulation tests
- Investigator believes treatment will provide survival benefit
You will not qualify if you...
- Active, known, or suspected autoimmune disease
- Uncontrolled hypertension with systolic BP >160 mmHg or diastolic BP >90 mmHg despite medication
- History of hereditary bleeding disorders or recent significant bleeding within 12 weeks before screening
- Uncontrolled cardiac symptoms or diseases
- Interstitial lung disease, drug-induced pneumonia, radiation pneumonitis, active pneumonia, or severe lung dysfunction
- Active hepatitis B or C infection above specified viral load thresholds
- Allergy to any study drugs
- Pregnant or breastfeeding women
- Any other condition that may cause premature study termination per investigator's judgment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China, 361003
Actively Recruiting
2
Zhangzhou Affiliated Hospital of Fujian Medical University
Zhangzhou, Fujian, China, 363099
Actively Recruiting
3
Hainan General Hospital
Haikou, Hainan, China, 570311
Actively Recruiting
Research Team
S
San-Gang Wu, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here